ReviewNeural regeneration research2018
Magnesium sulfate and fetal neuroprotection: overview of clinical evidence.
Review in Neural regeneration research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Defining the mechanisms of neuroinflammation and antepartum neuroprotection in human neural progenitor cells and microglia.AJOG global reports · 2026Article
- Magnesium Sulfate in Neonatal Hypoxic-Ischemic Encephalopathy: Bridging the Gap Between Molecular Neuroprotection and Clinical Outcomes.Current issues in molecular biology · 2026Review
- Urinary 6-sulfatoxymelatonin as a predictive biomarker for brain injury in very preterm infants.Scientific reports · 2026Article
- Magnesium sulfate in oxidative stress-associated pathologies: clinical, cellular, and molecular perspectives.Biophysical reviews · 2025Review
- The effect of Polybrominated diphenyl ethers at the fetal blood-brain-barrier: evaluation using a microphysiological system.Frontiers in cell and developmental biology · 2025Article
- A Narrative Review on Magnesium Sulfate as a Game Changer in Reducing ICU Stays in Organophosphate Poisoning Cases.Cureus · 2024Review
- Cross-sectional and prospective associations of early childhood circulating metals with early and mid-childhood cognition in the Project Viva cohort.Environmental research · 2024Article
- Review
- Antenatal Magnesium Sulfate Benefits Female Preterm Infants but Results in Poor Male Outcomes.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Augmented Placental Protein 13 in Placental-Associated Extracellular Vesicles in Term and Preterm Preeclampsia Is Further Elevated by Corticosteroids.International journal of molecular sciences · 2023Article
- Determinants of cerebral palsy in children: systematic review.Sudanese journal of paediatrics · 2023Review
- Effects of MgSOInternational journal of molecular sciences · 2022Article
- Maternal and fetal serum concentrations of magnesium after administration of a 6-g bolus dose of magnesium sulfate (MgSOActa obstetricia et gynecologica Scandinavica · 2022Article
- Neurobehavioral Phenotype and Dysexecutive Syndrome of Preterm Children: Comorbidity or Trigger? An Update.Children (Basel, Switzerland) · 2022Review
- Burden of Comorbidities and Healthcare Resource Utilization Among Medicaid-Enrolled Extremely Premature Infants.Journal of health economics and outcomes research · 2022Article
- Effects of Melatonin on Neurobehavior and Cognition in a Cerebral Palsy Model ofFrontiers in endocrinology · 2021Article
- Intraventricular Hemorrhage in Very Preterm Infants: A Comprehensive Review.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antenatal administration of magnesium sulfate is an important part of the neuroprotective strategy for preterm infants. Strong evidence from five randomized controlled trials and five meta-analyses has demonstrated that magnesium sulfate, when administered before preterm delivery, significantly reduces the risk of cerebral palsy at two years. Through secondary analyses of randomized controlled trials and other original clinical studies, this state-of-the-art review highlights the absence of serious adverse effects in both pregnant women and neonates, as well as the impact of maternal body mass index and preeclamptic status on the maternal and neonatal magnesium levels, which could influence the magnitude of the neuroprotective effect. Although antenatal magnesium sulfate is a cost-effective strategy, some practice surveys have demonstrated that the use of magnesium sulfate is not sufficient and that its use is heterogeneous, differing among different maternity wards. Since 2010, an increasing number of obstetrical societies have recommended its use to improve the neurological outcomes of preterm infants, especially the International Federation of Gynecology and Obstetrics and World Health Organization in 2015, and France in 2017. Considering the neuroprotective impact of magnesium sulfate when administered before delivery, postnatal administration should be considered, and its effects should be assessed using randomized controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.